Stryker Co. (NYSE:SYK - Get Free Report) Director Allan C. Golston sold 2,458 shares of the company's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total value of $941,586.06. Following the sale, the director now directly owns 14,895 shares of the company's stock, valued at $5,705,827.65. The trade was a 14.16 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Stryker Price Performance
SYK stock traded down $3.82 during trading on Friday, hitting $382.59. 1,268,413 shares of the stock traded hands, compared to its average volume of 1,388,856. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. The stock has a market cap of $145.99 billion, a price-to-earnings ratio of 49.30, a P/E/G ratio of 2.93 and a beta of 0.96. Stryker Co. has a one year low of $314.93 and a one year high of $406.19. The company has a 50 day simple moving average of $377.92 and a 200 day simple moving average of $368.21.
Stryker (NYSE:SYK - Get Free Report) last released its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, topping analysts' consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter last year, the firm posted $3.46 EPS. Equities analysts expect that Stryker Co. will post 13.49 EPS for the current fiscal year.
Stryker Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be issued a $0.84 dividend. The ex-dividend date is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.88%. Stryker's dividend payout ratio is 43.30%.
Analysts Set New Price Targets
SYK has been the subject of a number of research analyst reports. Piper Sandler reissued an "overweight" rating and set a $420.00 target price (up previously from $380.00) on shares of Stryker in a research report on Wednesday, October 30th. Robert W. Baird raised their target price on Stryker from $378.00 to $405.00 and gave the company an "outperform" rating in a report on Wednesday, October 30th. UBS Group upped their price target on Stryker from $366.00 to $370.00 and gave the stock a "neutral" rating in a report on Wednesday, October 30th. JPMorgan Chase & Co. raised their price objective on shares of Stryker from $420.00 to $445.00 and gave the stock an "overweight" rating in a research note on Wednesday, January 29th. Finally, Stifel Nicolaus upped their target price on shares of Stryker from $400.00 to $440.00 and gave the company a "buy" rating in a research note on Wednesday, January 29th. Five research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to data from MarketBeat, Stryker presently has an average rating of "Moderate Buy" and an average target price of $420.68.
Check Out Our Latest Stock Report on Stryker
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently added to or reduced their stakes in SYK. Chicago Capital LLC lifted its position in shares of Stryker by 3.1% during the fourth quarter. Chicago Capital LLC now owns 195,052 shares of the medical technology company's stock worth $70,228,000 after purchasing an additional 5,841 shares in the last quarter. Zhang Financial LLC lifted its holdings in Stryker by 55.0% during the 4th quarter. Zhang Financial LLC now owns 114,889 shares of the medical technology company's stock worth $41,366,000 after buying an additional 40,784 shares in the last quarter. Appleton Partners Inc. MA lifted its holdings in Stryker by 5.0% during the 4th quarter. Appleton Partners Inc. MA now owns 29,222 shares of the medical technology company's stock worth $10,521,000 after buying an additional 1,400 shares in the last quarter. Dale Q Rice Investment Management Ltd bought a new position in Stryker in the 4th quarter valued at $587,000. Finally, Berkshire Bank raised its position in shares of Stryker by 13.8% during the fourth quarter. Berkshire Bank now owns 8,489 shares of the medical technology company's stock worth $3,056,000 after acquiring an additional 1,030 shares during the last quarter. Institutional investors and hedge funds own 77.09% of the company's stock.
About Stryker
(
Get Free Report)
Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.
Featured Articles
Before you consider Stryker, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stryker wasn't on the list.
While Stryker currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
